Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
10 results
European journal of pediatrics, 13 2 2024 I will prevent disease whenever I can, for prevention is preferable to cure: doctors' role in the vaping epidemic. Borm FJ, Cohen S, Milani GP, de Winter P, Cohen D
Cited 1 times since 2023 (1.3 per year) source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 18, Issue 8, 1 1 2023, Pages 964-966 Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal? Borm FJ, Smit EF
Cited 2 times since 2023 (1.9 per year) source: EuropePMC
Oncoimmunology, Volume 12, Issue 1, 26 4 2023, Pages 2204745 Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes. Borm FJ, Smit J, Bakker J, Wondergem M, Smit EF, de Langen AJ, de Gruijl TD
Better biomarkers for programmed death - (ligand) 1 (PD-(L)1) checkpoint blockade in non-small cell lung cancer (NSCLC) are needed. We explored the predictive value of early response evaluation using Fluor-18-deoxyglucose positron emission tomography and pre- and on-treatment flowcytometric T-cell profiling in peripheral blood and tumor-draining lymph nodes (TDLN). The on-treatment evaluation was performed 7-14 days after the start of PD-1 blockade in NSCLC patients. These data were related to (... Abstract
Cited 2 times since 2022 (1.4 per year) source: EuropePMC
International journal of molecular sciences, Volume 24, Issue 1, 20 3 2022, Pages 21 Detection of Circulating Tumor Cells Using the Attune NxT. Gruijs M, Zeelen C, Hellingman T, Smit J, Borm FJ, Kazemier G, Dickhoff C, Bahce I, de Langen J, Smit EF, Hartemink KJ, van Egmond M
Circulating tumor cells (CTCs) have been detected in many patients with different solid malignancies. It has been reported that presence of CTCs correlates with worse survival in patients with multiple types of cancer. Several techniques have been developed to detect CTCs in liquid biopsies. Currently, the only method for CTC detection that is approved by the Food and Drug Administration is CellSearch. Due to low abundance of CTCs in certain cancer types and in early stages of disease, its clini... Abstract
Cited 5 times since 2022 (2.3 per year) source: EuropePMC
Life (Basel, Switzerland), Volume 12, Issue 3, 17 3 2022, Pages 446 Near-Infrared Fluorescence Tumor-Targeted Imaging in Lung Cancer: A Systematic Review. Neijenhuis LKA, de Myunck LDAN, Bijlstra OD, Kuppen PJK, Hilling DE, Borm FJ, Cohen D, Mieog JSD, Steup WH, Braun J, Burggraaf J, Vahrmeijer AL, Hutteman M
Lung cancer is the most common cancer type worldwide, with non-small cell lung cancer (NSCLC) being the most common subtype. Non-disseminated NSCLC is mainly treated with surgical resection. The intraoperative detection of lung cancer can be challenging, since small and deeply located pulmonary nodules can be invisible under white light. Due to the increasing use of minimally invasive surgical techniques, tactile information is often reduced. Therefore, several intraoperative imaging techniques... Abstract
Cited 27 times since 2021 (9.9 per year) source: EuropePMC
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Volume 63, Issue 5, 12 2 2021, Pages 686-693 PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer. Smit J, Borm FJ, Niemeijer AN, Huisman MC, Hoekstra OS, Boellaard R, Oprea-Lager DE, Vugts DJ, van Dongen GAMS, de Wit-van der Veen BJ, Thunnissen E, Smit EF, de Langen AJ
Better biomarkers are needed to predict treatment outcome in non-small cell lung cancer (NSCLC) patients treated with anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibitors. PD-L1 immunohistochemistry has limited predictive value, possibly because of tumor heterogeneity of PD-L1 expression. Noninvasive PD-L1 imaging using 89Zr-durvalumab might better reflect tumor PD-L1 expression. Methods: NSCLC patients eligible for second-line immunotherapy were enrolled. Patient... Abstract
Cited 8 times since 2021 (2.8 per year) source: EuropePMC
Cancers, Volume 13, Issue 12, 21 3 2021, Pages 3083 Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. Borm FJ, Smit J, Oprea-Lager DE, Wondergem M, Haanen JBAG, Smit EF, de Langen AJ
In multiple malignancies, checkpoint inhibitor therapy has an established role in the first-line treatment setting. However, only a subset of patients benefit from checkpoint inhibition, and as a result, the field of biomarker research is active. Molecular imaging with the use of positron emission tomography (PET) is one of the biomarkers that is being studied. PET tracers such as conventional 18F-FDG but also PD-(L)1 directed tracers are being evaluated for their predictive power. Furthermore,... Abstract
Cited 38 times since 2020 (10.9 per year) source: EuropePMC
Radiology, Volume 298, Issue 2, 17 3 2020, Pages E98-E106 Chest CT in the Emergency Department for Diagnosis of COVID-19 Pneumonia: Dutch Experience. Schalekamp S, Bleeker-Rovers CP, Beenen LFM, Quarles van Ufford HME, Gietema HA, Stöger JL, Harris V, Reijers MHE, Rahamat-Langendoen J, Korevaar DA, Smits LP, Korteweg C, van Rees Vellinga TFD, Vermaat M, Stassen PM, Scheper H, Wijnakker R, Borm FJ, Dofferhoff ASM, Prokop M
Background Clinicians need to rapidly and reliably diagnose coronavirus disease 2019 (COVID-19) for proper risk stratification, isolation strategies, and treatment decisions. Purpose To assess the real-life performance of radiologist emergency department chest CT interpretation for diagnosing COVID-19 during the acute phase of the pandemic, using the COVID-19 Reporting and Data System (CO-RADS). Materials and Methods This retrospective multicenter study included consecutive patients who presente... Abstract
Journal of thoracic disease, Volume 12, Issue 7, 1 1 2020, Pages 3883-3885 <sup>18</sup>F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer. Borm FJ, De Langen AJ
Cited 39 times since 2020 (9.3 per year) source: EuropePMC
Frontiers in oncology, Volume 10, 21 3 2020, Pages 187 Immunotherapy in Malignant Pleural Mesothelioma. de Gooijer CJ, Borm FJ, Scherpereel A, Baas P
The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most important immunotherapy-based research performed and put a focus on the future of MPM. PD-(L)1 inhibitors show response rates between 10 and 29% in phase II trials, with a wide range in progression free (PFS) and overall survival (OS).... Abstract